MedTrace Logo

Study of ASN004 in Patients With Advanced Solid Tumors

NCT04410224 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-07-10

No results posted yet for this study

Summary

Participants in this study will receive ASN004 once every 3 or 4 weeks by intravenous infusion. The ASN004 dosing schedule may be modified based on emerging data and Safety Review Committee decision. The study will test various doses of ASN004 to find out the highest safe dose to test in future trials.

Eligible subjects will be sequentially enrolled in cohorts at escalated doses.

Conditions

Interventions

DRUG

ASN004

ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.

Sponsors & Collaborators

  • Kirilys Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Alison L Hannah, MD · Kirilys Therapeutics Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-08
Primary Completion
2024-05-08
Completion
2024-05-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04410224 on ClinicalTrials.gov